Streetbeat News

Regulatory

SPRC

SciSparc shares rose following the submission of an IND application to the FDA for a Phase IIb trial of SCI-110, aimed at treating Tourette syndrome.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:12 pm

SPRC

SciSparc has submitted an Investigational New Drug (IND) application to the FDA for a Phase IIb trial of their drug SCI-110, aimed at treating Tourette Syndrome. This marks a significant step in the development of their treatment pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:10 pm

FDMT

4D Molecular Therapeutics (FDMT) presented positive clinical data for its 4D-150 treatment for wet AMD, showing significant reduction in injections and a favorable safety profile. The company is planning a Phase 3 program to enhance its clinical and commercial success.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:07 pm

XCUR

Exicure shares rose after the company announced it received an extension from the Nasdaq Hearings Panel, which is likely to provide the company more time to meet listing requirements.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:05 pm

XCUR

Exicure has received an extension from the Nasdaq Hearings Panel, allowing it more time to comply with Nasdaq's listing requirements. This development is crucial for Exicure as it works to maintain its listing status.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:02 pm

HYFM

Hydrofarm Holdings has been granted a 180-day extension by Nasdaq to comply with the minimum bid price rule. The new deadline for compliance is March 10, 2025.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:01 pm

EWJ

X

The White House has stated that the review process for Japan's Nippon Steel's proposed acquisition of U.S. Steel is ongoing, with no known delays or extensions.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 7:41 pm

ZBH

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) will phase out its CPT Hip System by the end of 2024 due to high fracture risks, following an FDA warning. The system has a higher fracture rate compared to similar devices, prompting a recall and updated usage instructions.

Portfolio Pulse from Vandana Singh

September 18, 2024 | 7:40 pm

SPY

Jeffrey Gundlach from Doubleline Capital stated in a CNBC interview that the Federal Reserve is not as far behind the curve as it was previously. This suggests a potential stabilization in monetary policy expectations.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 7:37 pm